To include your compound in the COVID-19 Resource Center, submit it here.

Theragnostics reports Phase I data for prostate cancer imaging agent

Theragnostics Ltd. (Bracknell, U.K.) said PET/CT imaging agent 68Ga-THP-PSMA did not lead to any

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE